HYDERABAD:
Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and developer of vaccines for infectious diseases, today announced that BBV152 (COVAXINÒ), its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study.
Bharat Biotech had conducted phase II/III, open-label, and multicenter studies to evaluate the safety, reactogenicity, and immunogenicity COVAXIN® in healthy children and adolescents in the 2-18 age group. The clinical trials conducted in the paediatric population between June 2021 to September 2021 have shown robust safety, reactogenicity, and immunogenicity. The data was submitted to the Central Drugs Standard Control Organisation (CDSCO) during October 2021 and received emergency use nod for children aged 12-18 from DCGI, recently.
In the study, no serious adverse event was reported. 374 subjects reported either mild or moderate severity symptoms with 78.6% getting resolved within 1 day. Pain at the injection site was the most commonly reported adverse event.
Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, “COVAXIN®’s clinical trial data from the pediatric population is very encouraging. Safety of the vaccine is critical for children, and we are glad to share that COVAXIN® has now proven data for safety and immunogenicity in children. We have now achieved our goal of developing a safe and efficacious COVID-19 vaccine for adults and children. Vaccines are a great preventive tool; the power of vaccines can only be harnessed if used prophylactically.”
more recommended stories
Ten cm Worm Removed Safely at KimshealthTHIRUVANANTHAPURAM:In a rare and precision driven.
DKMS Foundation India Launches Free HLA Typing for Children with ThalassaemiaBENGALURU:In a deeply emotional moment, ahead.
Children Who Undervent Liver Transplants Unite at KIMSHEALTHTHIRUVANANTHAPURAM:In a tribute to the life-saving.
India’s First Complex Airway Symposium Held at Amrita HospitalKOCHI:The Amrita Complex Airway Symposium, the.
MSN Laboratories Launches ‘SEMABESTHYDERABAD:MSN Laboratories today announced the launch.
9-Year-Old “Superhero” Triumphs Over Rare Blood Disorder at Kimshealth Cancer CentreTHIRUVANANTHAPURAM:KIMSHEALTH Cancer Centre recently celebrated a.
Aster Medcity Celebrates World Autism Awareness DayKOCHI:Aster Medcity’s Aster KIND (Kids Integrated.
India Autism Center Leads Dialogue on Lifelong Autism Care Through ‘Autism in Practice’KOLKATA:India Autism Center (IAC), a leading.
Neuberg Diagnostics Launches ‘Neubee’ – A Digital Health Companion to Simplify Preventive CareMUMBAI:Neuberg Diagnostics, one of India’s leading.
Post-Surgery Brain Development: National Seminar at AmritaKOCHI:Amrita Hospital, Kochi hosted a National.